Whole tumor antigen-loaded DCs have the advantage of allowing the presentation of multiple epitopes to MHC on DCs, thus inducing polyclonal T-cell responses from many potentially unknown tumor-associated antigens [34]. This evidence concerns the gene HLA-C and neoplasm.